Abbvie Applies for EMA Marketing Authorization for Migraine Drug Atogepant

The drugmaker Abbvie has applied to the European Medicines Agency (EMA) for marketing authorization for Atogepant, its prophylactic migrain treatment. Data supporting the application comes from two phase three studies, which showed the drug was well tolerated and was effective at reducing the occurrence of migraines.

According to Michael Gold, “Far too many people around the world are impacted from the debilitating challenges of migraine, which places a significant social and work-life burden for patients and care partners… If approved, atogepant will provide a prophylactic treatment option for adult migraine patients suffering for more than four days a month.”

To read more, click here.

(Source: PM Live, July 19th, 2022)